Company Performance - The company has not yet announced its full-year financial data for 2025, with an annual report expected to be released in early 2026. The Q3 2025 report shows revenue of 216.5 million and a net profit of 17.69 million, with attention needed on whether losses will further narrow and the recovery of overseas sales [2]. Industry Policy and Environment - The national "14th Five-Year Plan" clearly supports the development of innovative drugs and medical devices, with the smart home medical device market expected to exceed 90 billion by 2026. This policy may provide growth opportunities for the company's products, such as blood pressure monitors and nebulizers. However, international geopolitical conflicts have impacted overseas revenue, which saw a year-on-year decline of 9.72% in the first half of 2025 [3]. Company Business Status - The company primarily focuses on overseas markets, with 87.42% of its revenue coming from international sales in 2019. Attention is needed on the expansion of cross-border e-commerce and the operational efficiency of the "Lude Medical Health Smart Industry Park Project." The H1 2025 report indicates that the company is promoting lean management and optimizing production lines to enhance capacity utilization [4].